Original Query: "Hypothyroidism"
Previous Study | Return to List | Next Study

Effects of L-carnitine on Hypothyroidism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01769157
Recruitment Status : Completed
First Posted : January 16, 2013
Last Update Posted : December 4, 2013
IlDong Pharmaceutical Co Ltd
Information provided by (Responsible Party):
Sin Gon Kim, Korea University Anam Hospital

Brief Summary:
L-carnitine and thyroid hormone tended to antagonize reciprocally in human body. Urinary excretion of L-carnitine decreased in hypothyroid patients, and levothyroxine supplementation increased excretion of L-carnitine. The investigators hypothesized that supplying L-carnitine to hypothyroid patients with fatigue symptom could improve the quality of life, and fatigue score in them. Therefore, the investigators planned to compare the efficacy of L-carnitine and placebo in hypothyroid patients who had taken levothyroxine.

Condition or disease Intervention/treatment Phase
Hypothyroidism Drug: L-carnitine Drug: Placebo Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Single-center, Randomized, Double-Blinded, Comparative Study of the Effectiveness of L-carnitine in Patients'Fatigue Degree Changing With Hypothyroidism Who Take Levothyroxine
Study Start Date : August 2012
Primary Completion Date : June 2013
Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hypothyroidism
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: L-carnitine
L-carnitine 330mg, 3 tablet twice daily
Drug: L-carnitine
Placebo Comparator: Placebo
placebo drug, 3 tablet twice daily
Drug: Placebo

Primary Outcome Measures :
  1. Fatigue Severity scale [ Time Frame: baseline and 12 weeks ]
    Change from Baseline in Fatigue severity scale at 12 weeks (scoring `fatigue severity scale` at baseline and 12 weeks)

Secondary Outcome Measures :
  1. Wessely and Powell score [ Time Frame: baseline and 12 weeks ]
    Change from Baseline in Wessely and Powell score at 12 weeks (scoring `Wessely and Powell score` at baseline and 12 weeks)

Other Outcome Measures:
  1. thyroid function test [ Time Frame: baseline and 12 weeks ]
    measure thyroid-stimulating hormone and free T4 at baseline and 12 weeks

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of hypothyroidism with fatigue symptom
  • Currently use of the same amount of levothyroxine over at least six months
  • Normal serum free T4 level

Exclusion Criteria:

  • Current smoker
  • Serum hemoglobin level of under 12mg/dL
  • Clinical diagnosis of diabetes mellitus or fasting serum glucose level ≥ 126mg/dL or HbA1c level ≥ 6.5%
  • History of significant heart failure
  • History of large amount of alcohol consumption
  • Uncontrolled hypertension (systolic blood pressure ≥ 160 millimeter of mercury (mmHg) or diastolic blood pressure ≥ 100 mmHg
  • pregnant, or planning to be pregnant, or breast feeding women
  • aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 2 times of normal limit
  • serum Cr level > 2.0mg/dL

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01769157

Korea, Republic of
Korea University Anam Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Korea University Anam Hospital
IlDong Pharmaceutical Co Ltd

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Sin Gon Kim, Professor, Korea University Anam Hospital Identifier: NCT01769157     History of Changes
Other Study ID Numbers: LC-TH-1101
First Posted: January 16, 2013    Key Record Dates
Last Update Posted: December 4, 2013
Last Verified: December 2013

Additional relevant MeSH terms:
Thyroid Diseases
Endocrine System Diseases